Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
News|Articles|March 12, 2025
Blueprints for Better Care: 2024 Neurology Guideline Highlights
Author(s)Marco Meglio, Isabella Ciccone, MPH
Explore the key 2024 neurology guideline updates shaping clinical care across stroke, epilepsy, movement disorders, and more in this essential feature.
Advertisement
Advertisement
The field of neurology saw significant advancements in 2024, with new consensus guidelines introduced across various specialties, including stroke, epilepsy, neuromuscular conditions, and movement disorders. These updates reflect the growing body of research and evolving clinical practices, providing essential frameworks for improving patient care.
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
At a NeurologyLive Clinical Forum in Philadelphia, Jessica D. Schulte, MD, PhD, of NYU Grossman School of Medicine, discussed how earlier recognition and systemic therapy options are changing the treatment paradigm for patients with NF1-associated plexiform neurofibromas.
Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.
Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.
Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.
Advertisement
Advertisement